Pharmafile Logo
Pharmafocus logo
Advanced Search

Bristol-Myers Squibb

Showing 15 posts of 146 posts found.

bms

BMS looks to leverage real-world data, with Flatiron collab

May 3, 2018
Medical Communications, Sales and Marketing Bristol-Myers Squibb, Flatiron health, biotech, drugs, pharma, pharmaceutical

Bristol-Myers Squibb has extended its existing collaboration with Flatiron Health by three years and expanded the efforts both will be …

News

BMS pulls the plug on Phase 3 trials of IDO1 inhibitor

May 2, 2018
Research and Development BMS, Bristol-Myers Squibb, IDO1, opdivo, pharma, phase 3

Bristol-Myers Squibb has terminated two pivotal Phase 3 trials of BMS-986205, an IDO1 inhibitor acquired through its $800 million acquisition …

News
john_tsai

Novartis snatches Amgen and BMS veteran for CMO and Drug Development Head

April 19, 2018
Medical Communications Amgen, BMS, Bristol-Myers Squibb, Novartis, appointment, pharma

Dr John Tsai has been welcomed to the fold as Novartis’ new Head of Global Development and Chief Medical Officer, …

News
humacao_exterior

BMS restructure will transfer 90 jobs from NY state to Massachusetts and New Jersey

March 15, 2018
Manufacturing and Production BMS, Bristol-Myers Squibb, Massachusetts, New York, new jersey, pharma

Bristol-Myers Squibb has announced plans to relocate around 90 roles from the state of New York to facilities in Massachusetts …

News

BMS’ Opdivo and Yervoy combo better than chemo in halting lung cancer progression

February 6, 2018
Manufacturing and Production, Research and Development BMS, Bristol-Myers Squibb, NSCLC, Yervoy, lung cancer, opdivo, pharma

Bristol-Myers Squibb has revealed promising data from its ongoing Phase 3 study investigating the efficacy of Opdivo (nivolumab) in combination …

News

Bristol-Myers Squibb’s Yervoy scores EU approval in paediatric melanoma

January 23, 2018
Manufacturing and Production, Sales and Marketing BMS, Bristol-Myers Squibb, EU, Yervoy, pharma

Bristol-Myers Squibb has revealed that its immunotherapy Yervoy (ipilimumab) has received an expanded indication from the European Commission, approving the …

News

BMS partners again with the company behind Opdivo

December 14, 2017
Medical Communications, Sales and Marketing Bristol-Myers Squibb, biotech, drugs, opdivo, pharma, pharmaceutical

Bristol-Myers Squibb has once again struck a deal with Ono Pharmaceutical for multiple programs, seeking to discover a boost to …

News
humacao_exterior

BMS agrees deal on Opdivo availability through Cancer Drugs Fund for head and neck cancer

October 13, 2017
Sales and Marketing BMS, Bristol-Myers Squibb, CDF, Cancer Drugs Fund, NICE, opdivo, pharma, pharmaceutical

Thanks to successful negotiation of a managed access agreement, NICE has announced its recommendation of Bristol-Myers Squibb’s Opdivo (nivolumab) for …

News

BMS’ Opdivo to finally be made available to lung cancer patients in the UK

September 20, 2017
Research and Development, Sales and Marketing Bristol-Myers Squibb, NICE, biotech, drugs, opdivo, pharma, pharmaceutical

It is two and a half years since patients with lung cancer in the US were able to receive Bristol-Myers …

News
bms

BMS’ Opdivo gets a potential first-line boost in kidney cancer

September 8, 2017
Medical Communications, Research and Development Bristol-Myers Squibb, biotech, drugs, opdivo, pharma, pharmaceutical

Bristol-Myers Squibb has announced results from a Phase 3 trial showing that patients treated with Opdivo alongside Yervoy in patients …

News
bms_4

BMS hit by clinical trial hold from FDA

September 7, 2017
Medical Communications, Sales and Marketing Bristol-Myers Squibb, biotech, drugs, immunotherapy, opdivo, pharma, pharmaceutical

The FDA has placed a partial hold on clinical trials involving Bristol-Myers Squibb’s immunotherapy treatment, Opdivo, when used in combination …

News
merckwindowweb

MSD plays catch up with €464m deal for fledgling biotech

September 7, 2017
Sales and Marketing Bristol-Myers Squibb, MSD, biotech, drugs, keytruda, pharma, pharmaceutical

MSD has announced that it will acquire Rigontec, a three-year old German biotech, in a deal worth an initial €115 …

News
original

Bristol-Myers Squibb’s $2.3 billion gamble to boost cancer pipeline

August 4, 2017
Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, IFM Therapeutics, biotech, drugs, pharma, pharmaceutical

Bristol-Myers Squibb has agreed a deal to acquire IFM Therapeutics for a potential $2.3 billion. The latter is a biotech …

News
scotland_flag

SMC reverses decision on Opdivo for kidney cancer

June 12, 2017
Manufacturing and Production, Sales and Marketing BMS, Bristol-Myers Squibb, SMC, opdivo

The Scottish Medicines Consortium (SMC) has performed a U-turn on its decision regarding Opdivo (nivolumab), and will now allow patients …

News

BMS’ Opdivo scores eighth approval in Europe for bladder cancer

June 5, 2017
Research and Development, Sales and Marketing Bristol-Myers Squibb, Cancer, Europe, European Commission, bladder cancer, immunotherapy

Bristol-Myers Squibb has announced that its flagship immunotherapy treatment Opdivo (nivolumab) has secured its eighth approval in Europe as the …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023